Integral Health Asset Management LLC Buys 519,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Integral Health Asset Management LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 145.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 875,000 shares of the company’s stock after purchasing an additional 519,000 shares during the quarter. Integral Health Asset Management LLC owned approximately 1.76% of Mineralys Therapeutics worth $10,771,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its holdings in Mineralys Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after acquiring an additional 989 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Mineralys Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company’s stock valued at $2,645,000 after acquiring an additional 1,307 shares during the period. Northern Trust Corp raised its holdings in Mineralys Therapeutics by 0.7% during the fourth quarter. Northern Trust Corp now owns 246,113 shares of the company’s stock valued at $3,030,000 after acquiring an additional 1,688 shares during the period. Bank of New York Mellon Corp raised its holdings in Mineralys Therapeutics by 2.7% during the fourth quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company’s stock valued at $804,000 after acquiring an additional 1,711 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Mineralys Therapeutics by 19.1% in the fourth quarter. Wells Fargo & Company MN now owns 23,714 shares of the company’s stock worth $292,000 after purchasing an additional 3,802 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Trading Down 6.1%

Shares of MLYS stock opened at $14.65 on Monday. The stock’s 50-day moving average price is $13.98 and its 200-day moving average price is $12.41. Mineralys Therapeutics, Inc. has a 12-month low of $8.24 and a 12-month high of $18.38. The stock has a market capitalization of $950.43 million, a price-to-earnings ratio of -4.02 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Ratings Changes

MLYS has been the topic of several research reports. The Goldman Sachs Group reduced their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Guggenheim reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, HC Wainwright lifted their target price on Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, April 2nd.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total transaction of $129,729.42. Following the completion of the transaction, the chief financial officer now owns 215,340 shares in the company, valued at $2,597,000.40. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Malcom Rodman sold 55,771 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the transaction, the insider now owns 116,704 shares of the company’s stock, valued at $1,839,255.04. This trade represents a 32.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,213 shares of company stock worth $1,360,567 over the last 90 days. Company insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.